Details for New Drug Application (NDA): 020533
✉ Email this page to a colleague
NDA 020533 describes NAROPIN, which is a drug marketed by Fresenius Kabi Usa and is included in one NDA. It is available from three suppliers. There are three patents protecting this drug and three Paragraph IV challenges. Additional details are available on the NAROPIN profile page.
The generic ingredient in NAROPIN is ropivacaine hydrochloride. There are thirteen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the ropivacaine hydrochloride profile page.
The generic ingredient in NAROPIN is ropivacaine hydrochloride. There are thirteen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the ropivacaine hydrochloride profile page.
Summary for 020533
| Tradename: | NAROPIN |
| Applicant: | Fresenius Kabi Usa |
| Ingredient: | ropivacaine hydrochloride |
| Patents: | 3 |
Pharmacology for NDA: 020533
| Physiological Effect | Local Anesthesia |
Suppliers and Packaging for NDA: 020533
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| NAROPIN | ropivacaine hydrochloride | SOLUTION;INJECTION | 020533 | NDA | Henry Schein, Inc. | 0404-9924 | 0404-9924-30 | 1 VIAL, SINGLE-DOSE in 1 BAG (0404-9924-30) / 30 mL in 1 VIAL, SINGLE-DOSE |
| NAROPIN | ropivacaine hydrochloride | SOLUTION;INJECTION | 020533 | NDA | General Injectables & Vaccines, Inc | 52584-286 | 52584-286-35 | 1 VIAL, SINGLE-DOSE in 1 BAG (52584-286-35) / 30 mL in 1 VIAL, SINGLE-DOSE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INJECTION | Strength | 20MG/10ML (2MG/ML) | ||||
| Approval Date: | May 1, 1998 | TE: | AP | RLD: | Yes | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INJECTION | Strength | 40MG/20ML (2MG/ML) | ||||
| Approval Date: | Sep 24, 1996 | TE: | AP | RLD: | Yes | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INJECTION | Strength | 100MG/20ML (5MG/ML) | ||||
| Approval Date: | May 1, 1998 | TE: | AP | RLD: | Yes | ||||
Expired US Patents for NDA 020533
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Fresenius Kabi Usa | NAROPIN | ropivacaine hydrochloride | SOLUTION;INJECTION | 020533-001 | May 1, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Fresenius Kabi Usa | NAROPIN | ropivacaine hydrochloride | SOLUTION;INJECTION | 020533-005 | Sep 24, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Fresenius Kabi Usa | NAROPIN | ropivacaine hydrochloride | SOLUTION;INJECTION | 020533-007 | Sep 24, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Fresenius Kabi Usa | NAROPIN | ropivacaine hydrochloride | SOLUTION;INJECTION | 020533-001 | May 1, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Fresenius Kabi Usa | NAROPIN | ropivacaine hydrochloride | SOLUTION;INJECTION | 020533-004 | Sep 24, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Fresenius Kabi Usa | NAROPIN | ropivacaine hydrochloride | SOLUTION;INJECTION | 020533-004 | Sep 24, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
